Role of Natural and Synthetic Compounds in Modulating NRF2/KEAP1 Signaling Pathway in Prostate Cancer.
Giovanni TossettaSonia FantoneDaniela MarzioniRoberta MazzucchelliPublished in: Cancers (2023)
Prostate cancer is the second most common cancer in men worldwide. Prostate cancer can be treated by surgery or active surveillance when early diagnosed but, when diagnosed at an advanced or metastatic stage, radiation therapy or androgen-deprivation therapy is needed to reduce cancer progression. However, both of these therapies can cause prostate cancer resistance to treatment. Several studies demonstrated that oxidative stress is involved in cancer occurrence, development, progression and treatment resistance. The nuclear factor erythroid 2-related factor 2 (NRF2)/KEAP1 (Kelch-Like ECH-Associated Protein 1) pathway plays an important role in protecting cells against oxidative damage. Reactive oxygen species (ROS) levels and NRF2 activation can determine cell fate. In particular, toxic levels of ROS lead physiological cell death and cell tumor suppression, while lower ROS levels are associated with carcinogenesis and cancer progression. On the contrary, a high level of NRF2 promotes cell survival related to cancer progression activating an adaptive antioxidant response. In this review, we analyzed the current literature regarding the role of natural and synthetic compounds in modulating NRF2/KEAP1 signaling pathway in prostate cancer.
Keyphrases
- prostate cancer
- oxidative stress
- signaling pathway
- papillary thyroid
- cell death
- radical prostatectomy
- reactive oxygen species
- induced apoptosis
- squamous cell
- radiation therapy
- nuclear factor
- dna damage
- minimally invasive
- squamous cell carcinoma
- pi k akt
- coronary artery disease
- lymph node metastasis
- stem cells
- anti inflammatory
- cell proliferation
- toll like receptor
- atrial fibrillation
- acute coronary syndrome
- bone marrow
- diabetic rats
- endoplasmic reticulum stress